Oliver J Ott1, Vratislav Strnad2, Guido Hildebrandt3, Daniela Kauer-Dorner4, Hellen Knauerhase5, Tibor Major6, Jaroslaw Łyczek7, José Luis Guinot8, Jürgen Dunst9, Cristina Gutierrez Miguelez10, Pavel Slampa11, Michael Allgäuer12, Kristina Lössl13, Bülent Polat14, György Kovács15, Arnt-René Fischedick16, Thomas G Wendt17, Rainer Fietkau18, Rolf-Dieter Kortmann19, Alexandra Resch6, Anna Kulik20, Leo Arribas8, Peter Niehoff21, Ferran Guedea10, Annika Schlamann19, Richard Pötter6, Christine Gall22, Martina Malzer22, Wolfgang Uter22, Csaba Polgár6. 1. Department of Radiation Oncology, University Hospital Erlangen, Germany. Electronic address: oliver.ott@uk-erlangen.de. 2. Department of Radiation Oncology, University Hospital Erlangen, Germany. 3. Department of Radiation Oncology, University Hospital Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Germany. 4. Department of Radiation Oncology, University Hospital AKH Wien, Austria. 5. Department of Radiation Oncology, University Hospital Rostock, Germany. 6. Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. 7. Brachytherapy Department, Centrum Onkologii - Instytut im Marii Skłodowskej, Warsaw, Poland; Podkarpacki Hospital Cancer Center Brzozów, Poland. 8. Department of Radiation Oncology, Valencian Institute of Oncology, Spain. 9. Department of Radiation Oncology, University Hospital Kiel, Germany. 10. Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain. 11. Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 12. Department of Radiation Oncology, Hospital Barmherzige Brüder Regensburg, Germany. 13. Department of Radiation Oncology, University Hospital Inselspital Bern, Switzerland. 14. Department of Radiation Oncology, University Hospital Würzburg, Germany. 15. Interdisciplinary Brachytherapy Unit, University Hospital Lübeck/UKSH Campus Lübeck, Germany. 16. Department of Radiation Oncology, Clemenshospital, Münster, Germany. 17. Department of Radiation Oncology, University Hospital Jena, Germany. 18. Department of Radiation Oncology, University Hospital Erlangen, Germany; Department of Radiation Oncology, University Hospital AKH Wien, Austria. 19. Department of Radiation Oncology, University Hospital Leipzig, Germany. 20. Brachytherapy Department, Centrum Onkologii - Instytut im Marii Skłodowskej, Warsaw, Poland. 21. Department of Radiation Oncology, University Hospital Kiel, Germany; Department of Radiotherapy, Municipal Hospital Cologne, University Witten-Herdecke, Germany. 22. Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Germany.
Abstract
BACKGROUND AND PURPOSE: To compare early side effects and patient compliance of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to external beamwhole breast irradiation (WBI) in a low-risk group of patients with breast cancer. MATERIAL AND METHODS:Between April 2004 and July 2009, 1328 patients with UICC stage 0-IIA breast cancer were randomized to receive WBI with 50Gy and a boost of 10Gy or APBI with either 32.0Gy/8 fractions, or 30.1Gy/7 fractions (HDR-brachytherapy), or 50Gy/0.60-0.80Gy per pulse (PDR-brachytherapy). This report focuses on early side-effects and patient compliance observed in 1186 analyzable patients. ClinicalTrials.gov identifier: NCT00402519. RESULTS:Patient compliance was excellent in both arms. Both WBI and APBI were well tolerated with moderate early side-effects. No grade 4 toxicity had been observed. Grade 3 side effects were exclusively seen for early skin toxicity (radiation dermatitis) with 7% vs. 0.2% (p<0.0001), and breast infection with 0% vs. 0.2% (p=n.s.) for patients treated with WBI and APBI. The incidence of grades 1-2 early side effects for WBI and APBI was 86% vs. 21% (p<0.0001) for skin toxicity, 2% vs. 20% (p<0.0001) for mild hematoma, and 2% vs. 5% (p=0.01) for mild breast infection rates, respectively. No differences had been found regarding grades 1-2 early breast pain (26% vs. 29%, p=0.23). CONCLUSIONS:APBI with interstitial multicatheter brachytherapy was tolerated very well and dramatically reduced early skin toxicity in comparison to standard WBI.
RCT Entities:
BACKGROUND AND PURPOSE: To compare early side effects and patient compliance of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to external beam whole breast irradiation (WBI) in a low-risk group of patients with breast cancer. MATERIAL AND METHODS: Between April 2004 and July 2009, 1328 patients with UICC stage 0-IIA breast cancer were randomized to receive WBI with 50Gy and a boost of 10Gy or APBI with either 32.0Gy/8 fractions, or 30.1Gy/7 fractions (HDR-brachytherapy), or 50Gy/0.60-0.80Gy per pulse (PDR-brachytherapy). This report focuses on early side-effects and patient compliance observed in 1186 analyzable patients. ClinicalTrials.gov identifier: NCT00402519. RESULTS:Patient compliance was excellent in both arms. Both WBI and APBI were well tolerated with moderate early side-effects. No grade 4 toxicity had been observed. Grade 3 side effects were exclusively seen for early skin toxicity (radiation dermatitis) with 7% vs. 0.2% (p<0.0001), and breast infection with 0% vs. 0.2% (p=n.s.) for patients treated with WBI and APBI. The incidence of grades 1-2 early side effects for WBI and APBI was 86% vs. 21% (p<0.0001) for skin toxicity, 2% vs. 20% (p<0.0001) for mild hematoma, and 2% vs. 5% (p=0.01) for mild breast infection rates, respectively. No differences had been found regarding grades 1-2 early breast pain (26% vs. 29%, p=0.23). CONCLUSIONS:APBI with interstitial multicatheter brachytherapy was tolerated very well and dramatically reduced early skin toxicity in comparison to standard WBI.
Authors: Pierfrancesco Franco; Giuseppe Carlo Iorio; Sara Bartoncini; Mario Airoldi; Corrado De Sanctis; Isabella Castellano; Umberto Ricardi Journal: Med Oncol Date: 2018-04-03 Impact factor: 3.064
Authors: Krishan R Jethwa; Sean S Park; Karthik Gonuguntla; Stephanie M Wick; Laura A Vallow; Christopher L Deufel; Thomas J Whitaker; Keith M Furutani; Kathryn J Ruddy; Kimberly S Corbin; Tina J Hieken; Robert W Mutter Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-27 Impact factor: 7.038
Authors: Daniela Alterio; Eliana La Rocca; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa; Stefania Volpe; Anna Maria Camarda; Alessia Casbarra; William Russell-Edu; Maria Alessia Zerella; Roberto Orecchia; Viviana Galimberti; Paolo Veronesi Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Cameron W Swanick; Xiudong Lei; Ying Xu; Yu Shen; Nathan A Goodwin; Grace L Smith; Sharon H Giordano; Kelly K Hunt; Reshma Jagsi; Simona F Shaitelman; Susan K Peterson; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-09 Impact factor: 7.038
Authors: Tobias Forster; Clara Victoria Katharina Köhler; Jürgen Debus; Juliane Hörner-Rieber Journal: Breast Care (Basel) Date: 2020-02-21 Impact factor: 2.860
Authors: Chandler Scott Cortina; Ashley A Woodfin; Laurel L Tangalakis; Xuanji Wang; Jennifer D Son; Jennifer Poirier; Ruta Rao; Katherine Kopkash; Andrea Madrigrano Journal: Breast Care (Basel) Date: 2020-07-13 Impact factor: 2.268
Authors: S Garduño-Sánchez; I Villanego-Beltrán; M Dolores de Las Peñas-Cabrera; J Jaén-Olasolo Journal: Clin Transl Oncol Date: 2021-07-02 Impact factor: 3.405